Sorry for the delay in responding to your questions about qualifying gene mutation for targeted therapy with a PARP inhibitor. The trial,I was in required study participants to have either a germline or somatic BRCA1, BRCA2 or PALB2 mutation, have failed at least one first-line standard of care treatment and be sensitive to a platin agent.